We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
-16.43%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$791B
AUM Growth
-$200B
Cap. Flow
-$11.4B
Cap. Flow %
-1.44%
Top 10 Hldgs %
26.42%
Holding
3,063
New
88
Increased
1,490
Reduced
1,207
Closed
101

Top Buys

Rank Stock Value
1
BDX icon
Becton Dickinson
BDX
+$3.46B
2
UNH icon
UnitedHealth
UNH
+$2.79B
3
CRM icon
Salesforce
CRM
+$2.38B
4
SHW icon
Sherwin-Williams
SHW
+$1.41B
5
PM icon
Philip Morris
PM
+$1.34B

Sector Composition

Rank Sector Weight
1 Technology 26.68%
2 Healthcare 19.49%
3 Consumer Discretionary 13.07%
4 Financials 11.17%
5 Communication Services 8.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
OMIC
2826
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$60K ﹤0.01%
522
+27
+5% +$3.17K
RUBY
2827
DELISTED
Rubius Therapeutics, Inc
RUBY
$60K ﹤0.01%
70,400
-914,246
-93% -$1.53M
ENDP
2828
DELISTED
Endo International plc
ENDP
$60K ﹤0.01%
128,452
-425
-0.3% -$540
BORR
2829
Borr Drilling
BORR
$1.24B
$59K ﹤0.01%
+12,823
New +$63.7K
JNCE
2830
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$59K ﹤0.01%
19,618
-44,691
-69% -$217K
VAPO
2831
DELISTED
Vapotherm, Inc. Common Stock
VAPO
$58K ﹤0.01%
2,844
+901
+46% +$33K
XERS icon
2832
Xeris Biopharma Holdings
XERS
$1.56B
$56K ﹤0.01%
36,634
+12,634
+53% +$26.7K
HIL
2833
DELISTED
Hill International, Inc. Common Stock
HIL
$56K ﹤0.01%
33,200
QNCX icon
2834
Quince Therapeutics
QNCX
$32.9M
$55K ﹤0.01%
123
+51
+71% +$36K
QUAD icon
2835
Quad
QUAD
$517M
$55K ﹤0.01%
20,024
+3,324
+20% +$16.1K
RFL icon
2836
Rafael Holdings
RFL
$110M
$55K ﹤0.01%
29,731
-619
-2% -$1.23K
TONX
2837
TON Strategy Co
TONX
$154M
$55K ﹤0.01%
13
+3
+30% +$13.5K
EXTN
2838
DELISTED
Exterran Corporation
EXTN
$55K ﹤0.01%
12,700
-11,600
-48% -$70.2K
KULR icon
2839
KULR Technology Group
KULR
$143M
$54K ﹤0.01%
4,388
AVPT icon
2840
AvePoint
AVPT
$2.78B
$53K ﹤0.01%
+12,290
New +$62.4K
NVVE
2841
DELISTED
Nuvve Holding Corp
NVVE
0
ORGN
2842
DELISTED
Origin Materials
ORGN
$52K ﹤0.01%
+338
New +$64.5K
APRN
2843
DELISTED
Blue Apron Holdings, Inc. Class A Common Stock
APRN
$52K ﹤0.01%
+1,183
New +$48.2K
VLTA
2844
DELISTED
Volta Inc.
VLTA
$52K ﹤0.01%
39,960
+24,960
+166% +$55.7K
SFT
2845
DELISTED
Shift Technologies, Inc. Class A Common Stock
SFT
$52K ﹤0.01%
7,730
+3,493
+82% +$42.9K
QUMU
2846
DELISTED
Qumu Corp.
QUMU
$52K ﹤0.01%
64,950
+12,200
+23% +$14.8K
IZEA icon
2847
IZEA Worldwide
IZEA
$53.4M
$51K ﹤0.01%
14,275
-5,175
-27% -$22.3K
PHUN icon
2848
Phunware
PHUN
$43.6M
$51K ﹤0.01%
938
+614
+190% +$51.3K
SMRT icon
2849
SmartRent
SMRT
$278M
$51K ﹤0.01%
+11,353
New +$57.3K
BFX
2850
DELISTED
BowFlex Inc.
BFX
$51K ﹤0.01%
28,900
+15,184
+111% +$42K

Similar funds

T. Rowe Price Associates's Q2 2022 Portfolio in Review

As of Q2 2022, T. Rowe Price Associates held 3,063 positions worth $791B, down 20% from $992B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

T. Rowe Price Associates's Q2 2022 filing shows 88 new, 1,490 increased, 1,207 reduced and 101 closed positions. Its largest new stake was ESAB: 6,073,363 shares worth $266M. The largest sale was Meta Platforms (Facebook), an estimated $4.44B.

By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q2 2022 buy was ESAB: 6,073,363 shares worth $266M.
  • T. Rowe Price Associates added most to Becton Dickinson in Q2 2022, an estimated $3.46B increase.
  • T. Rowe Price Associates's biggest Q2 2022 reduction was Meta Platforms (Facebook), cutting an estimated $4.44B.
  • T. Rowe Price Associates fully exited Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q2 2022, selling an estimated $364M.
  • T. Rowe Price Associates's ten largest holdings make up 26% of its $791B portfolio in Q2 2022.
  • T. Rowe Price Associates opened 88 new positions and closed 101 in Q2 2022.
  • T. Rowe Price Associates's portfolio value fell 20% quarter-over-quarter to $791B.

Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.